Skip to main content

Table 1 Clinical characteristics and outcome of 27 patients with high-risk neuroblastoma

From: Whole exome sequencing reveals novel somatic alterations in neuroblastoma patients with chemotherapy

No.

Age

Month

Gender

Primary site

BM

N-MYC amplification

Tumor reduction

FU

Outcome

RE1

RE2 (%)

1

39

F

R

Y

N

80%

94

14

CR

2

28

F

R

Y

Y

53%

63

17

Dead

3

30

M

R

Y

Y

94%

99

12

Dead

4

24

F

R

Y

Y

70%

91

19

CR

5

84

M

R

Y

Y

0%

0

17

PR

6

38

F

R

Y

Y

51%

60

20

PR

7

61

F

R

Y

N

41%

64

16

PR

8

36

M

P

Y

Y

79%

79

18

PR

9

39

F

R

Y

Y

72%

77

18

PR

10

19

F

R

N

N

88%

93

21

PR

11

78

M

R

Y

N

70%

89

25

PR

12

30

M

R

N

Y

47%

82

14

Dead

13

40

F

R

N

N

49%

57

13

PR

14

19

F

R

N

N

63%

50

6

Dead

15

59

F

R

Y

N

86%

99

22

CR

16

49

M

P

N

Y

60%

97

13

Dead

17

39

M

R

Y

N

75%

86

16

PR

18

48

M

R

Y

Y

29%

35

18

PR

19

23

F

R

Y

Y

25%

50

5

Dead

20

54

F

R

Y

N

50%

60

13

PR

21

69

F

R

Y

N

60%

80

14

VGPR

22

41

F

R

N

N

0

22

15

PR

23

101

M

P

Y

N

0

15

20

Stable

24

61

M

R

Y

Y

71%

92

20

CR

25

36

F

R

Y

N

50%

81

19

VGPR

26

15

M

R

Y

N

67%

96

21

CR

27

31

M

R

Y

Y

71%

95

14

Dead

  1. R retroperitoneum and renicapsule, P posterior mediastinum, FU follow up